Aranesp Has High Mortality Rate In New Study

Lee Coleman
Lee Coleman
Contributor
Posted by Lee ColemanJanuary 29, 2007 4:19 PM

Amgen who makes Aranesp sent a letter out to healthcare professionals about a study it had conducted. The study showed it was ineffective in reducing RBC transfusions in patients with anemia not due to concurrent chemotherapy. It also showed a higher mortality in patients who were receiving Aranesp. This study was done comparing the medication with a placebo. This study was done to establish of the effectiveness in a new indication for Aranesp of reducing RBC transfusions. It is approved for anemia that is caused by chemotherapy treatment.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Bowling Green

InjuryBoard Bowling Green RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Legal Assistance Center

More Info
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address